

e594



Arizona, Tucson, Arizona, ⁴Division of Dermatology, Department of Medicine, University of California Los Angeles, Los Angeles, California USA

REFERENCES

- Saunte DM, Boer J, Stratigos A *et al.* Diagnostic delay in hidradenitis suppurativa is a global problem. *Br. J. Dermatol.* 2015; **173**: 1546–9.
- 2. Kokolakis G, Wolk K, Schneider-Burrus S *et al.* Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. *Dermatology* 2020; **256**: 421–30.
- Price KN, Thompson AM, Rizvi O *et al.* Complementary and alternative medicine use in patients with hidradenitis suppurativa. *JAMA Dermatol.* 2020; 156: 345–8.
- 4. Wong CA, Merchant RM, Moreno MA. Using social media to engage adolescents and young adults with their health. *Health-care* 2014; 2: 220–4.
- 5. Koumaki D, Efthymiou O, Bozi E *et al.* Perspectives on perceived stigma and self-stigma in patients with hidradenitis suppurativa. *Clin. Cosmet. Investig. Dermatol.* 2019; **12**: 785–90.

doi: 10.1111/ajd.13714

Research Letter

Dear Editors,

Impact of the COVID-19 pandemic on dermatology practice in the Philippines: A cross-sectional study

Since the first local case of COVID-19 was reported in the Philippines in March 2020,¹ varying degrees of community quarantine have been implemented by the national government. In the most restrictive enhanced community quarantine (ECQ), essential medical services were prioritised and only non-aesthetic dermatology clinics were allowed. Aesthetic services were allowed after 5 months (August 2020) in areas under the less restrictive general community quarantine (GCQ) and modified GCQ (MGCQ).² Safety guidelines in outpatient clinics were prescribed by local authorities and specialty societies.^{2–4} The impact of these changes on dermatology practice in the country has not been evaluated.

To assess the impact of the COVID-19 pandemic on dermatology practice, we conducted an analytical cross-sectional study using an online questionnaire among members of the Philippine Dermatological Society (PDS) from September 25 to December 31 2020. At this time, new cases ranged from 700 to 3500 per day¹ and most areas were under GCQ or MGCQ. Results were analysed using Stata version 14. Comparative analyses were done using paired ttest or Mann–Whitney U-test for quantitative variables, and chi-square test or Fisher exact test for qualitative variables.

Funding: None.

Normalcy of data was tested using Shapiro–Wilk test. Significance levels were set at *P*-value < 0.05.

Of 1037 PDS members, 305 completed our questionnaire. Table 1 shows the demographic profile of the respondents. Table 2 shows the changes in consultation practices before and during the pandemic. During the pandemic, 15% saw patients purely via teledermatology (TD), 15% saw all their patients face-to-face (FTF) and 70% utilised both. Our respondents reported more than 50% decrease in clinic hours and number of patients seen during the pandemic. Those utilising TD increased 6-fold. There were no changes in the three most seen pathologic and aesthetic concerns before and during the pandemic (Supplemental S1). Our results parallel the findings of previous studies documenting the impact of the pandemic on dermatology practice, including a decrease in clinic days, decrease in patients seen FTF and an increase in TD utilisation.^{5–9} The 6-fold increase in TD utilisation in our study is notable, which may be due to the extended period of restrictions. Most physicians used Viber and Facebook messenger for TD consults, reflecting their primary considerations in choosing TD platforms. Similarly, other reports reflect the use of 'informal' TD platforms, such as WhatsApp, Zoom, Skype, Facetime, Facebook and Viber.^{6,10}

Half of those who saw inpatients before ceased to do so during the pandemic which may be due to their fear of acquiring COVID-19 in the hospital or due to fewer dermatology admissions as hospital beds were diverted to COVID-19 patients. To augment the overwhelmed workforce, 8% went on duty in COVID-19 facilities. Similarly,

 Table 1
 Demographic profile of the respondents

	n (%) or mean (SD) n = 305
Age, in years	48.05 (±9.63)
30–39	74 (24%)
40-49	88 (29%)
50–59	106 (35%)
$\geq \! 60$	37 (12%)
Gender	
Male	26 (8.52%)
Female	279 (91.48%)
Geographic location of practice	
Luzon	260 (85.25%)
National Capital Region (NCR)	241 (79%)
Outside NCR	19 (6.23%)
Visayas	18 (5.90%)
Mindanao	27 (8.85%)
Clinic location*	
Mall	108 (35.41%)
Government hospital	41 (13.44%)
Private hospital	170 (55.74%)
Stand-alone clinic	132 (43.28%)
Multispecialty clinic	11 (3.61%)
Others	5 (1.64%)
Type of practice	
Aesthetic	1 (0.33%)
Pathologic	37 (12.13%)
Aesthetic and pathologic	267 (87.54%)

*Respondents were instructed to select all that apply.

Conflict of interest: The authors have no conflicts of interest to declare.

	Before COVID-19 pandemic n = 260	During COVID-19 pandemic n = 260	<i>P</i> -value
Clinic hours per week [mean (SD)]	26.02 (±12.46)	12.23 (±8.47)	<0.0001
Patients seen per week [median	40 (IQR 25-60)	15 (IQR 8–25)	<0.0001
% of patients seen by appointment [mean (SD)]	34 (±30.80)	73 (±32.52)	<0.0001
Duration of patient co	nsultation $[n (\%)]$		
Decreased	1 ()]	176 (68)	
Increased		13 (5)	
No change		71 (27)	
Respondents	(n = 305)	(n = 305)	< 0.0001
who utilised teledermatology [n (%)]	43 (14)	260 (85)	
		n (%) n = 260	
Type of teledermatolo	gy		
Hybrid		156 (60)	
Real-time interactiv	e	67 (26) 77 (14)	
Store-and-forward	oting tolodormatal	37 (14) a gy platforma*	
Ease of use for notic	ecting teledermator	ogy platform*	
Ease of use for dam	ents natologist	209 (60)	
Cost	natologist	161 (62)	
Data privacy		83 (32)	
Technical support		23 (9)	
Other		4 (2)	
Teledermatology platf	orm**		
Viber		161 (63)	
Facebook messenge	r	149 (57)	
Zoom		48 (18)	
SeriousMD***		45 (17)	
Medifi***		37 (14)	
Google Meet		28 (11)	
Doxy.me***		26 (10)	
Hospital-provided p	latform	9 (3)	
Utner Eastern considered to		3(1)	
ractors considered to	see	(n = 213)	
teledermatology**	ilisteau oi		
Difficulty in online patient assessmen	ıt	156 (73)	
Patient's request		134 (62)	
Perform urgent proc	cedure	115 (53)	
Local government u	init	94 (44)	
has allowed clinic	operation		
Rapidly progressing	disease	85 (40)	
Not responding to the	reatment	77 (36)	
Perform aesthetic p	rocedure	69 (32)	
Patient does not hav	/e	8 (4)	
access to teledern	natology		
Other		6 (3)	

IQR, interquartile range; SD, standard deviation.

Doxy.me are dedicated teleconsultation platforms.

**Respondents were instructed to select all that apply.

*Respondents were instructed to select up to 3 considerations.

agement software which has teleconsultation function. Medifi and

***SeriousMD is an electronic medical record and practice man-

 Table 2
 Consultation practices before and during the COVID-19
 pandemic

 Table 5
 Procedural practices before and during the COVID-19

 pandemic

	Before COVID-19 pandemic <i>n</i> (%) <i>n</i> = 260	During COVID-19 pandemic n (%) n = 260	<i>P</i> -value
Number of non-aesthetic pro	ocedures		
Decreased		235 (90)	
Increased		10 (4)	
No change		8 (3)	
Performed non-aesthetic procedures	260 (100)	248 (95)	<0.0001
Type of non-aesthetic	(n = 260)	(n = 248)	
procedure	. ,	. ,	
Electrodessication	251 (97)	140 (56)	< 0.0001
Biopsy	229 (88)	138 (56)	< 0.0001
Excision	153 (59)	82 (33)	< 0.0001
Cryotherapy	70 (27)	37 (15)	< 0.001
Mohs' surgery	7 (3)	5 (3)	0.616
Other	36 (14)	7 (3)	< 0.0001
Number of aesthetic procedu	ires		
Decreased		241 (93)	
Increased		4 (2)	
No change		4 (2)	
Not applicable*		7 (3)	
Performed aesthetic	253 (97)	235 (90)	0.001
procedures			
Type of aesthetic	(n = 253)	(n = 235)	
procedure			
Acne surgery	244 (96)	124 (53)	< 0.0001
Chemical peel	229 (90)	128 (54)	< 0.0001
Laser/energy-	186 (74)	112 (48)	< 0.0001
based device			
Botulinum toxin injection	172 (68)	113 (48)	<0.0001
Microneedling	144 (57)	53 (23)	< 0.0001
Sclerotherapy	88 (35)	27 (11)	< 0.0001
Soft tissue augmentation	69 (27)	39 (17)	0.005
PRP injection	42 (17)	19 (8)	0.004
Scar revision	42 (17)	17 (7)	0.002
Other	11 (4)	6 (3)	0.028

PRP, platelet-rich plasma.

*Did not perform aesthetic procedures.

Conforti and colleagues ⁷ reported that 11% of their respondents worked in COVID-19 departments.

Table 3 shows the changes in procedural practices before and during the pandemic. During the pandemic, 95% and 90% of our respondents still performed non-aesthetic and aesthetic procedures respectively. This may be due to the timing of our survey during which safety protocols for dermatology clinics were more established and quarantine protocols were less restrictive. However, most reported a decrease in procedures performed, with a median decrease of 75% (IQR 50%–90%) and 80% (IQR 50%– 90%) in non-aesthetic and aesthetic procedures respectively. This may be due to the decrease in their clinic hours and allotment of time in between procedures for air flow and disinfection, thus limiting the number of procedures per day.

Respondents implemented various engineering and administrative control measures (Supplemental S2). Some

© 2021 The Australasian College of Dermatologists

of the personal protective equipment used significantly differed according to risk of exposure (Supplemental S3).

Ninety-six per cent of the respondents reported a decrease in weekly income, with a median decrease of 60% (IQR 50%-75). Twenty-nine per cent ventured into alternate sources of income: e-commerce and sales (69%), stocks and investments (24%), real estate (13%), practice of non-dermatological profession (9%) and others (7%).

Limitations of our study include possible recall and nonresponse biases due to the methodology. Another is that 79% practice in the National Capital Region, the region with the most cases. It is possible that respondents who were profoundly affected by the pandemic were more motivated to complete our survey.

Our study shows the profound impact of the COVID-19 pandemic and the ensuing safety measures on dermatology practice in the Philippines, specifically in terms of consultation practices, hospital practices, procedural practices, infection control and income. In addition, it shows how TD can be utilised to complement FTF consults for dermatologists to continue to provide care to patients in this pandemic.

ACKNOWLEDGEMENTS

We would like to thank our content experts, Dr. Charmaine Castillo, Dr. Nancy Garcia-Tan, Dr. Victoria Guillano, Dr. Zharlah Gulmatico-Flores and Dr. Jacqueline Melendres for helping us TO validate our questionnaire.

ETHICS APPROVAL

This study was approved by the University of the East Ramon Magsaysay Memorial Medical Center Research Institute for Health Sciences Ethics Review Committee (ERC approval number: 0869/H/2020/097).

Camille Angeles¹ Lim⁵ | Czarina Chavez² Bryan Guevara⁴ | Lian Jamisola¹ ¹University of the East Ramon Magsaysay Memorial Medical Center Inc., Quezon City, ²Rizal Medical Center, Pasig, ³Cebu Institute of Medicine, Cebu City and ⁴Southern Philippines Medical Center, Davao City, Philippines

REFERENCES

- 1. World Health Organization. *Philippines: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data* | *WHO Coronavirus (COVID-19) Dashboard With Vaccination Data.* https://covid19.who.int/region/wpro/country/ph. Accessed August 17, 2021.
- Department of Trade and Industry Philippines. *Memorandum Circular No. 20-44.*; 2020. https://www.officialgazette.gov.ph/2020/07/31/memorandum-circular-no-20-44-s-2020/.
- Philippine Society for Microbiology and Infectious Diseases, Philippine Hospital Infection Control Society, Philippine College of Physicians. *Infection Prevention and Control Guidelines for Outpatient Clinic Resumption in the Context of COVID-19.*; 2020.
- Philippine Dermatological Society. *Re-opening your dermatology practice post-COVID-19 quarantine: PDS interim recommenda-tions.* https://pds.org.ph/dermatology-practice-post-quarantine-pds-recommendations. Published 2020. Accessed May 25, 2021.

- Lambertini M, Patrizi A, Peris K *et al.* The impact of the COVID-19 pandemic on dermatologic practice: an Italian survey. *Eur J Dermatol* 2021; **31**: 55–9. https://doi.org/10.1684/ejd. 2021.3970.
- Bhargava S, McKeever C, Kroumpouzos G. Impact of COVID-19 pandemic on dermatology practices: Results of a web-based, global survey. *Int J Women's Dermatol.* 2021; 7: 217–23. https:// doi.org/10.1016/j.ijwd.2020.09.010
- Conforti C, Lallas A, Argenziano G et al. Impact of the COVID-19 pandemic on dermatology practice worldwide: results of a survey promoted by the International Dermoscopy Society (IDS). Dermatol Pract Concept 2021; 11: e2021153. https://doi. org/10.5826/dpc.1101a153.
- Misery L, Fluhr J, Beylot-Barry M et al. Psychological and professional impact of COVID-19 lockdown on French dermatologists: Data from a large survey. Ann Dermatol Venereol 2021; 148: 101–5. https://doi.org/10.1016/j.annder.2021.01.004.
- Litchman GH, Marson JW, Rigel DS. The continuing impact of COVID-19 on dermatology practice: Office workflow, economics, and future implications. *J Am Acad Dermatol* 2021; 84: 576–9. https://doi.org/10.1016/j.jaad.2020.08.151.
- Moscarella E, Pasquali P, Cinotti E *et al.* A survey on teledermatology use and doctors' perception in times of COVID-19. *J Eur Acad Dermatology Venereol* 2020; **34**: e772–3. https://doi. org/10.1111/jdv.16843.

Supporting Information

Additional Supporting Information may be found online in Supporting Information:

 Table S1. Most common pathologic and aesthetic concerns
 seen before and during the COVID-19 pandemic.

Table S2. Engineering and administrative control measures utilized during the COVID-19 pandemic.

 Table S3. Personal protective equipment used according to risk of exposure.

doi: 10.1111/ajd.13681

Research Letter

Dear Editors,

Australian Teledermatology experience during COVID-19

In March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic [1]. Victoria declared a 'state of emergency', restrictions including a

Correspondence: Johannes S Kern, Dermatology Department, The Royal Melbourne Hospital, Parkville, Victoria, Australia. Email: johannes.kern@mh.org.au

Funding source: None.

Conflict of interest: The Royal Melbourne Hospital Foundation received an unrestricted grant for Fellowship support for a Dermatology Rural Outreach Registrar from Janssen-Cilag Pty Ltd. Janssen-Cilag Pty Ltd had no role in the study design, data collection, data analysis, interpretation of data, writing of the manuscript or publication decisions.